Efficacy and Safety of Oral Gonadotropin-Releasing Hormone Antagonist, Relugolix, in Endometriosis: A Meta-Analysis of Randomized Clinical Trials

Milene Vitória Sampaio Sobral, João Pedro Pereira dos Santos, Dos Santos JPP, Vilela TAA, Tania Aparecida Alves Vilela, Rafaela da Cunha Pirolla, Pirolla RDC, Barreiros FA, Fernando Augusto Barreiros, Marina Ayabe Gomes de Moraes, de Moraes MAG
American journal of therapeutics · 2025 · vol. 32(3) , pp. e309–e312 · doi:10.1097/MJT.0000000000001842 · PMID:40338696
other OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated deep summary by claude@2026-06, 2026-06-19 · read from full text ⓘ

This meta-analysis of randomized clinical trials evaluated the efficacy and safety of oral the gonadotropin-releasing hormone antagonist relugolix for treating endometriosis, pooling outcomes across included studies. The authors report an overall assessment of relugolix’s benefits and adverse-event profile, synthesizing evidence from trial data rather than observational cohorts. A key limitation is that meta-analytic results depend on the quality and heterogeneity of the underlying randomized trials. This paper is centrally about endometriosis — it specifically synthesizes randomized evidence for relugolix’s efficacy and safety in endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 765 characters · extracted from oa-doi-fallback · click to expand
Sobral, Milene Vitória Sampaio; dos Santos, João Pedro Pereira; Vilela, Tania Aparecida Alves ; Pirolla, Rafaela da Cunha; Barreiros, Fernando Augusto MD, PhD; de Moraes, Marina Ayabe Gomes MD, MSc University of West São Paulo, São Paulo, Brazil The authors state that they have no proprietary interest in the products named in this article. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. During the preparation of this work, the authors used ChatGPT 3.5 to enhance the readability and language of the text. After using this tool/service, the authors reviewed and edited the content as needed and assume full responsibility for the content of the published article.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-08-05T06:13:34.187606+00:00
pubmed
last seen: 2026-08-05T06:10:25.529145+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine